Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474937 | 0.87 | HDAC1 (0.50) | MAPTTP53PTGDR2LMNAMEN1 | |
| SCHEMBL7220006 | 0.85 | MAPT (0.54) | MAPTPTGDR2MEN1KMT2AKDM4E | |
| SCHEMBL6474125 | 0.84 | PTGDR2 (0.64) | PTGDR2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL6484850 | 0.83 | LMNA (0.56) | MAPTTP53PTGDR2LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL6474427 | 0.83 | MAPT (0.52) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL7227315 | 0.83 | PTGDR2 (0.47) | MAPTTP53PTGDR2MEN1KMT2A | |
| SCHEMBL7219447 | 0.79 | SMN1; SMN2 (0.56) | MAPTTP53PTGDR2LMNAMEN1 | |
| SCHEMBL6480721 | 0.77 | PTGDR2 (0.58) | PTGDR2MEN1KMT2AKDM4EGLA | |
| SCHEMBL6480665 | 0.77 | KDM4E (0.60) | PTGDR2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL6483292 | 0.76 | PTGDR2 (0.58) | PTGDR2MEN1KMT2AKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583135-B2 | Treating central nervous system disorders wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). | PHARMACIA & UPJOHN COMPANY | 2003-06-24 | — | — | US | disclosed |